Fig. 1
Antitumor activity and immune response upon intratumoral ISF35 treatment. Mice bearing 8-day s.c. B16.F10 tumors were treated on day 0, 4, 8, and 12 with ISF35 or control rAd/PBS. a Tumor growth (n = 10). b Mouse survival (n = 10). c Tumor growth after i.t. treatment with agonistic CD40 mAb or ISF35 (n = 8). d–f Myeloid cell numbers and activation in tumor 5 days after initiation of ISF35 or PBS treatment. g Intratumoral cytokines and chemokines 7 days after initiation of ISF35 or rAd or PBS treatment, measured by Luminex from a tumor supernatant (n = 5). Data are representative of at least two independent experiments and analyzed by unpaired two-tailed t test or one-way ANOVA. *P < 0.05, **P < 0.005, ***P < 0.0005 and ****P < 0.00005. Error bars are SEM. Survival analysis was performed with the log-rank test
